Thursday, February 16, 2017
Clinerion and ASUS Life signed a strategic alliance. Clinerion and ASUS Life, together with the Show Chwan Healthcare System, will deliver innovative services for the efficient running of clinical trials, clinical patient recruitment, market access and real-world evidence in Taiwan.
Daiichi Sankyo Company, Limited has announced its decision to close its research subsidiary, Daiichi Sankyo India Pharma Private Limited, to increase R&D productivity.
Eisai and Keio University have entered into a new joint research agreement for the discovery and development of new drugs targeting dementia. For this collaborative research, a research lab will be established, and researchers from Eisai and Keio University will work together to identify and validate novel drug targets and biomarkers that could potentially lead to the development of new therapeutics and preventive medicines for dementia.
Novogene, a commercial provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise; AITbiotech, a Singapore biotechnology company; and the Genome Institute of Singapore (GIS) have announced that NovogeneAIT Genomics Singapore (NovogeneAIT) a new joint venture between Novogene and AITbiotech will establish a joint whole genome sequencing (WGS) center at Biopolis, Singapore.
Clinigen, a global pharmaceuticals and services group, has launched its Japanese business with the opening of an office in Tokyo, Japan. The establishment of Clinigen K.K. further expands the Group’s presence in Asia, following Clinigen’s acquisition of Link Healthcare in 2015. Alongside the launch, Clinigen K.K. will transfer the Marketing Authorisation for its lead Specialty Pharmaceutical (SP) product Foscavir (foscarnet sodium) back from Nobel Pharma on 1 November 2016. Nobel Pharma has been the distribution partner for Foscavir in Japan since 2011.
Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced that Peking Union Medical College (PUMC) Hospital in Beijing, China, and Keio University in Tokyo, Japan have become Phoenix Centers of Excellence.
Crescendo Biologics, the drug discovery and developer of Humabody-based therapeutics, and Takeda Pharmaceutical has announced a global, strategic, multi-target collaboration and license agreement for the discovery, development and commercialization of Humabody-based therapeutics for cancer indications with a high unmet medical need.
To address the growing global demand for clinical services, Thermo Fisher Scientific has announced the official opening of its new state-of-the-art GMP1 standard facility in South Korea. Strategically located in Seoul, the new site will provide local, regional and global pharmaceutical and biotech companies with a one-stop service for clinical supplies—from cGMP storage, local labelling, secondary packaging, comparator sourcing, handling and distribution of ambient and cold chain supplies to clinical site returns management.
The IMS Institute for Healthcare Informatics has announced the launch of a new branch focused on supporting improved health outcomes across Asia. Based in Singapore, the team will forge relationships in the public and private sectors and apply analytics-driven approaches, based on Real-World Evidence, for disease modeling and insights—providing regional markets with much-needed tools to make better and more cost-effective healthcare policy decisions.